MaaT Pharma to Hold Annual General Meeting on June 20, 2025 Lyon, France, May 14, 2025 – 7:30am CET –…
Categorie
Financial
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive results from Phase 3 trial…
May 13, 2025
Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Lyon, France, April 14, 2025 – 6.00pm CET – MaaT Pharma…
April 14, 2025
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co Lyon, France, April 7, 2025 –…
April 7, 2025
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co Lyon, France, April 7th, 2025 –…
April 7, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
April 4, 2025
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results Positive results from…
March 27, 2025
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease The…
January 8, 2025
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
January 7, 2025
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes Completion of enrollment in the European…
November 5, 2024
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.